-

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.

The dividend is payable on August 3, 2026, to stockholders of record at the close of business on July 2, 2026.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb Announces Dividend
Release Versions

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

More News From Bristol Myers Squibb

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Second Quarter Financial Results for 2026...

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma...
Back to Newsroom